Evaluation of the safety of CEdiranib in the prevention of Bowel perforation in platinum-resistant Ovarian Cancer
Latest Information Update: 01 Mar 2023
At a glance
- Drugs Cediranib (Primary) ; Olaparib; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Acronyms CEBOC
- 06 Feb 2023 The overall end date was changed from 29/04/2022 to 28/02/2023.
- 30 Apr 2022 Status changed from active, no longer recruiting to completed.
- 03 Aug 2020 Planned End Date changed from 31 Aug 2020 to 29 Apr 2022.